Hormetic Dose Response of NaAsO2 on Cell Proliferation of Prostate Cells in Vitro: Implications for Prostate Cancer Initiation and Therapy

Sodium meta-arsenite (NaAsO2) has been suggested to play a role both in initiation/progression of prostate cancer and as a future antiprostate cancer drug. We have studied the effects of NaAsO2 on cell proliferation of prostate cancer and noncancer cells, breast cancer cells, and adrenocortical carcinoma cells in vitro. Further, we have investigated the effect of NaAsO2 on the androgen receptor. We report that NaAsO2 alters the cell proliferation of prostate cells, in a hormetic manner, by increasing cell proliferation at low concentrations and decreasing the cell proliferation at high concentrations. No activation of the androgen receptor was detected. We conclude that NaAsO2 is able to increase cell proliferation of prostate cells in vitro at low concentrations, while it decreases cell viability at high concentrations. This novel finding has to be further addressed if NaAsO2 should be developed into an antiprostate cancer drug.

[1]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[2]  Baoxin Li,et al.  Dual effects of arsenic trioxide on tumor cells and the potential underlying mechanisms , 2018, Oncology letters.

[3]  C. Lynch,et al.  Low‐level arsenic exposure from drinking water is associated with prostate cancer in Iowa , 2017, Environmental research.

[4]  Choung-Soo Kim,et al.  Downregulation of androgen receptors by NaAsO2 via inhibition of AKT‐NF‐κB and HSP90 in castration resistant prostate cancer , 2017, The Prostate.

[5]  B. Ardalan,et al.  In the War Against Solid Tumors Arsenic Trioxide Need Partners , 2014, Journal of Gastrointestinal Cancer.

[6]  C. Schmidt.  Low-Dose Arsenic: In Search of a Risk Threshold , 2014, Environmental health perspectives.

[7]  Choung-Soo Kim,et al.  Sodium meta-arsenite induces reactive oxygen species-dependent apoptosis, necrosis, and autophagy in both androgen-sensitive and androgen-insensitive prostate cancer cells , 2014, Anti-cancer drugs.

[8]  B. Howard,et al.  Arsenic Exposure and Cancer Mortality in a US-Based Prospective Cohort: The Strong Heart Study , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[9]  Y. Ning,et al.  Telomere and Microtubule Targeting in Treatment-Sensitive and Treatment-Resistant Human Prostate Cancer Cells , 2012, Molecular Pharmacology.

[10]  H. Katus,et al.  Novel roles for hERG K+ channels in cell proliferation and apoptosis , 2011, Cell Death and Disease.

[11]  M. Edelman,et al.  KML001 Cytotoxic Activity Is Associated with Its Binding to Telomeric Sequences and Telomere Erosion in Prostate Cancer Cells , 2008, Clinical Cancer Research.

[12]  L. Benbrahim-Tallaa,et al.  Inorganic Arsenic and Human Prostate Cancer , 2007, Environmental health perspectives.

[13]  Y. Ju,et al.  Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. , 2001, The Journal of nutrition.

[14]  S. Haslam,et al.  Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. , 1998, Cancer research.

[15]  C. J. Chen,et al.  Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. , 1990, Cancer research.

[16]  T. Kuo,et al.  ARSENIC AND CANCERS , 1988, The Lancet.

[17]  W. McGuire,et al.  Phytoestrogen interaction with estrogen receptors in human breast cancer cells. , 1978, Endocrinology.

[18]  M. Denison,et al.  Recombinant cell bioassays for endocrine disruptors: development of a stably transfected human ovarian cell line for the detection of estrogenic and anti-estrogenic chemicals. , 2000, In vitro & molecular toxicology.